There is increasing evidence that the shaping of the immunological tolerance that goes awry in autoimmune disease is heavily influenced by commensal microbiota. Although this relationship between the microbiome and autoimmunity has been studied for autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, it has not been investigated for autoimmune uveitis, a potentially blinding inflammatory condition affecting the eyes. Studying the relationship of the microbiome with uveitis may reveal important insights into the pathogenesis of this disease, but more importantly, may result in potential intervention through the use of novel treatment strategies. The hypothesis of this study is that altering the gut flora will affect the clinical severity of uvitis.
The first aim to test this hypothesis involves administering broad-spectrum antibiotics to reduce gut flora and to determine how and why this affects uveitis disease severity. Two animal models of autoimmune uveitis, experimental autoimmune uveitis (EAU), and aggrecan-induced uveitis will be tested for this purpose. Disease severity, relative abundances of bowel microorganisms, and the contribution of regulatory T lymphocytes will be assessed. To evaluate the microbiota, a well-developed rapid but robust technique to quantitatively characterize the microbiome of complex biological environments, such as the gut, will be used (Biome representational in silico karyotyping or BRISK). In the second and third aims, the effects of probiotics (commensal microrganisms that can regulate self-tolerance) and prebiotics (diets that affect the innate microbiome in a specific way) will be investigated for their effects on clinical disease severity and the ability to alter gut flora in the disease models above.

Public Health Relevance

The goal of this project is to explore the potential effects of altering non disease-causing microorganisms present in the gut on a potentially blinding inflammatory eye condition, uveitis, through the use of antibiotics, probiotics, or specific diets. This is relevant to public health because uveitis causes up to 10% of all cases of blindness, and this proposal suggests well known, safe methods to potentially alter the course of this disease.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08EY022948-02
Application #
8581350
Study Section
Special Emphasis Panel (ZEY1-VSN (06))
Program Officer
Agarwal, Neeraj
Project Start
2012-12-01
Project End
2017-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
2
Fiscal Year
2014
Total Cost
$208,947
Indirect Cost
$15,478
Name
Oregon Health and Science University
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Campbell, J Peter; Davis, Stephen; Flaxel, Christina et al. (2014) Acquired drusenoid deposits on infrared imaging as a sign of vitreoretinal lymphoma. Ocul Immunol Inflamm 22:161-3
Lin, Phoebe; Suhler, Eric B; Rosenbaum, James T (2014) The future of uveitis treatment. Ophthalmology 121:365-76
Rosenbaum, James T; Lin, Phoebe; Asquith, Mark et al. (2014) Does the microbiome play a causal role in spondyloarthritis? Clin Rheumatol 33:763-7
Lin, Phoebe; Bach, Mary; Asquith, Mark et al. (2014) HLA-B27 and human ?2-microglobulin affect the gut microbiota of transgenic rats. PLoS One 9:e105684
Beardsley, Robert M; Suhler, Eric B; Rosenbaum, James T et al. (2013) Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother 14:411-24